The short version of WADA fits in a sentence. The long version — which is the one that helps — is below.
Reviewed 2025-10-14. Anything still debated is marked as such rather than presented as settled.
Several misconceptions surround SR9009. It is often described as a SARM, a steroid, or an exercise pill, but its known target is the REV-ERB receptor family. Rodent studies have examined exercise capacity and metabolic markers, yet human outcomes remain unproven. Oral bioavailability appears low in animals, and human pharmacokinetics are not well characterized. Online products may contain impurities or different compounds, so identity and purity testing are important for research use.
Analytical chemists detect SR9009 with liquid chromatography-tandem mass spectrometry, commonly abbreviated LC-MS/MS. Sample preparation may involve protein precipitation, liquid-liquid extraction, or solid-phase extraction before analysis. Laboratories can target the parent compound or its metabolites, depending on the matrix and the purpose of testing. Anti-doping methods require sensitive and specific assays because concentrations in biological samples can be low. Reference standards and validated methods are essential for reliable identification and quantification.
SR9009 is generally described as poorly soluble in water and more soluble in organic solvents such as dimethyl sulfoxide and ethanol. Stock solutions are commonly prepared in an organic solvent before dilution into an aqueous buffer or vehicle. Precipitation can occur if the organic fraction is reduced too quickly or if the final concentration exceeds the compound's solubility limit. Sonication or gentle warming may aid dissolution in some protocols, but excessive heat can promote degradation. Container material and pH can also influence observed solubility.
For long-term storage, SR9009 is typically kept as a solid at low temperature, protected from moisture and light. Desiccated conditions limit hydrolysis, while opaque containers reduce photochemical breakdown. Solutions are less stable than solids and are often stored frozen in aliquots to avoid repeated freeze-thaw cycles. Stability data are not standardized across all suppliers, so users should rely on certificate-of-analysis information when available. Degradation may appear as color change, precipitate, or decreased chromatographic purity.
Laboratory identification of SR9009 typically relies on chromatographic separation coupled to mass spectrometry, often with ultraviolet detection as a secondary check. Nuclear magnetic resonance spectroscopy can confirm molecular structure when a reference standard is available. Because many suppliers sell the compound as a research chemical, independent identity testing is important for experimental reproducibility. A single retention time is not sufficient proof of identity, especially when related compounds may be present. Purity assessments usually report a percentage based on area normalization.
| Property | Value | Notes |
|---|---|---|
| Regulatory status | Not approved for human use | Research-use-only status in many markets |
| WADA status | Prohibited in sport | Generally listed as a non-approved substance |
| Detection technique | LC-MS/MS | Common for urine and blood analysis |
| Common alias | Stenabolic | Informal market nickname, not a pharmacopoeial name |
| Purity check | HPLC or LC-UV | Independent certificate of analysis is typical |
SR9009 is a synthetic small molecule developed as a REV-ERB agonist. It binds to REV-ERBα and REV-ERBβ, nuclear receptors that help regulate circadian rhythms and metabolic gene expression. In cell and animal studies, the compound alters lipid and glucose handling and influences skeletal muscle oxidative capacity. Its exact effects in humans remain largely uncharacterized because controlled clinical trials have not been reported. The molecule is frequently described in preclinical literature as a metabolic modulator.
Research interest in SR9009 grew from studies showing improved running endurance in mice after short treatment periods. Those experiments linked the compound to increased mitochondrial content and fatty acid oxidation in muscle, but the findings come from animal models and specific dosing schedules. Independent replication has been limited, and the pathways connecting REV-ERB activation to exercise performance are still being mapped. Whether similar responses occur in humans is an open question.
Research interest in SR9009 grew from studies of circadian biology and metabolic disease. Preclinical reports describe effects on exercise capacity, muscle metabolism, and blood lipid levels in rodents, but these findings come from controlled laboratory settings. The compound has low oral bioavailability in animals, which limits systemic exposure after swallowing. Investigators often use injected routes in experiments to achieve measurable plasma concentrations. Human clinical data are sparse, no approved therapeutic product exists, and whether animal effects translate to humans remains an open question.
Regulatory and sporting contexts treat SR9009 as a prohibited substance in many elite competitions. Its presence on banned lists reflects concerns about performance enhancement and unknown long-term safety. Analytical chemists have developed methods to detect the parent compound and its metabolites in urine and blood. Literature discussions distinguish between in vitro potency, animal pharmacology, and anecdotal human reports. The latter are difficult to verify because products sold online may lack purity or contain different compounds.
SR9009 is a synthetic small molecule studied as an agonist of the nuclear receptors REV-ERBα and REV-ERBβ. These receptors help regulate circadian rhythms, lipid metabolism, and inflammatory gene expression. In cell and animal experiments, SR9009 alters transcription of clock-controlled genes and metabolic pathways. The compound is not a hormone and does not resemble classical steroid structures. Its activity depends on binding to the ligand-binding domain of REV-ERB, where it can modify corepressor recruitment.
Regulatory treatment of SR9009 varies by country and context. It is not approved as a therapeutic drug by agencies such as the United States Food and Drug Administration or the European Medicines Agency. Sports authorities list it as a prohibited substance; the World Anti-Doping Agency classifies it among hormone and metabolic modulators. Legal status for personal possession or sale differs across jurisdictions, and some countries may restrict it under analog or research chemical laws. Buyers who seek verified material often rely on independent laboratory testing because online product labels may not match contents.
Laboratory samples of SR9009 are typically handled as research chemicals rather than pharmaceuticals. Suppliers usually state that the material is for research use only and not for human or veterinary administration. Storage recommendations generally call for a freezer at approximately −20 °C, protection from light, and a desiccated environment. The solid is often described as a white to off-white powder. Solubility is commonly reported in organic solvents such as dimethyl sulfoxide and ethanol, with low solubility in water.
Analytical identification and purity assessment often use high-performance liquid chromatography with ultraviolet detection or mass spectrometry. Liquid chromatography–tandem mass spectrometry is used to detect and quantify SR9009 in biological matrices, including urine and blood, for anti-doping or pharmacokinetic studies. Nuclear magnetic resonance spectroscopy can confirm molecular structure. Stability depends on form and storage: the solid is generally more stable than solutions, and repeated freeze–thaw cycles may degrade samples. Purity is typically reported as a percentage from a certificate of analysis.
Colombia returned to CONMEBOL competition at the 1957 South American Championship in Lima, a seven-team round-robin from which Bolivia and Paraguay had withdrawn, and finished fifth with four points from six matches under coach Pedro López. Heavy defeats to Argentina (2–8) on 13 March and Brazil (0–9) on 24 March left the side with ten goals scored and 25 conceded, but two victories provided encouragement. On 17 March, Carlos Arango scored in the 28th minute to beat reigning champions Uruguay 1–0 before 50,000 spectators at the Estadio Nacional, and the campaign closed on 1 April with a 4–1 win over Ecuador in which Delio Gamboa scored twice. Arango and Gamboa finished as Colombia's joint top scorers with three goals each, while goalkeeper Efraín Sánchez and defender Francisco Zuluaga started every match after the opening fixture.
== Education == Lectka completed his bachelor's in chemistry and graduated from Oberlin College in 1985. He completed his doctoral degree in organic chemistry from Cornell University in 1991. He then completed his postdoctoral studies as an Alexander von Humboldt Postdoctoral Fellow at the University of Heidelberg in Germany and then as a National Institutes of Health Postdoctoral Fellow at Harvard University.
=== Genetic instability === Considerable research has been funneled into the biological implications relating to the presence of H-DNA in the major breakpoint regions (Mbr) and double-strand-breakpoints of certain genes. Recent work has linked the presence of non-B-DNA structures with cases of genetic instability. Polypurine mirror-repeat H-DNA forming sequences were found neighboring the P1 promoter of the c-MYC gene and are associated with the major breakpoint hotspots of this region. Cases of genetic instability were also observed in the F1 offspring of transgenic mice after incorporation of human H-DNA-forming sequences paired with Z-DNA sequences into their genomes where no instability was previously reported. Additionally, formation of R.R.Y. H-DNA conformations have been observed at the Mbr of the bcl-2 gene. Formation of these structures has been posited to cause the t(14;18) translocation observed in many cancers and most follicular lymphomas. This observation has led to research that indicated a substantial decrease in translocation events can be observed after blocking the formation of H-DNA by altering the sequence of this region slightly. Long tracts of GAA·TTC have also been observed to form very stable H-DNA structures. Interactions between these two H-DNA structures, termed sticky DNA, has been shown to interrupt transcription of the X25, or frataxin gene. As decreased levels of the protein frataxin is associated with Friedreich's ataxia, formation of this instability has been suggested to be the basis for this genetic disease.
== Epidemiology == As of 2020, approximately 800 cases of FOP have been confirmed worldwide, making FOP one of the rarest diseases known. However, statistical estimates place the true number closer to several thousand. While historical estimates placed the global prevalence of FOP at 0.5 cases per million people, more recent studies suggest this is an underestimate as a result of underdiagnosis in FOP reporting. A 2021 study estimated the adjusted prevalence in the United States as 0.88 per million residents, while a 2017 study in France found a prevalence of 1.36 per million. Reported regional estimates can differ significantly, from 0.04 per million in Asia to 0.65 per million in North America. This is attributed largely to disparities in healthcare and patient identification, not actual genetic variation as it affects all ethnicities.
Sources: en.wikipedia.org
Olivia Thirlby as Cassandra Anderson:A rookie Judge and genetic mutant with powerful psychic abilities. Anderson can sense the thoughts and emotions of others. Thirlby contrasted her character with Dredd's "black and white" perspective, describing Anderson as existing "in a grey area where everything is enhanced or clouded by the fact [that] she knows what is going on in the very interior of a person". She undertook weapons and combat training, learning to perform a roundhouse kick to make her believably physically commanding. The character was partially inspired by singer Debbie Harry. Lena Headey as Madeline "Ma-Ma" Madrigal: A former prostitute turned drug lord and criminal kingpin who is the sole supplier of "Slo-Mo", a new and addictive drug. Headey's performance was inspired by punk-rock singer Patti Smith. Reich described the character as someone who does "not care at all about what anybody thinks or feels and she will do, and behave, as she wants". Headey said: "I think of [Ma-Ma] like an old great white shark who is just waiting for someone bigger and stronger to show up and kill her ... she's ready for it. In fact, she can't wait for it to happen ... She's an addict, so she's dead in that way, but that last knock just hasn't come." Before Headey's casting, the character was envisioned as a heavily made-up, scarred and obese older woman. Wood Harris as Kay: Ma-Ma's clansman. Harris described the character as a villain, but one that sees himself as no worse than the Judges. Harris said: " ...
On 30 June 2018, Charlie Rowley and Dawn Sturgess were found unconscious at a house in Amesbury, Wiltshire, about eight miles from the Salisbury poisoning site. On 4 July 2018, police said that the pair had been poisoned with the same nerve agent as ex-Russian spy Sergei Skripal. On 8 July 2018, Sturgess died as a result of the poisoning. Rowley regained consciousness and began recovering in hospital. He told his brother Matthew the nerve agent had been in a small perfume or aftershave bottle, which they had found in a park about nine days before spraying themselves with it. The police later closed and fingertip-searched Queen Elizabeth Gardens in Salisbury.
=== Pharmacokinetics === Absorption of topical corticosteroids depends on several factors such as the vehicle, or delivery system used by the drug, the integrity of the epidermal barrier, and whether or not an occlusive bandage is used in combination with the drug. The absorption of topical betamethasone dipropionate is theoretically minuscule; however, if absorbed it follows the same pharmacokinetic profile as is typical of systemic corticosteroids. It is metabolized primarily by the liver by hydrolysis to its metabolites betamethasone 17-monopropionate (primary) and betamethasone and the 6β-hydroxy derivatives of those metabolites, and it is excreted primarily by the kidneys.
Sources: en.wikipedia.org
Legality depends on the country and the intended use. In many places it is not approved as a medicine and may be sold only as a research chemical. Importation or possession can be restricted, and sports organizations prohibit it.
Anti-doping laboratories typically use LC-MS/MS to detect SR9009 or its metabolites in urine or blood. The exact assay depends on the laboratory and the testing program. Detection can be challenging because the compound may be rapidly metabolized and present at low levels.
Stenabolic is an informal nickname used in online fitness and research-chemical markets, not an official drug name. It likely references reported effects on endurance in rodent studies. The nickname does not imply approval or proven human benefit.
Liquid chromatography with mass spectrometry is a common approach. Ultraviolet detection and nuclear magnetic resonance can support identification when suitable standards are available.